Colin Sandercock

About Colin Sandercock

Colin G. Sandercock is Senior Vice President, General Counsel and Secretary of Cue Biopharma, serving in this role since December 2017; he is 68 years old and holds a B.S. in Chemistry and Mathematics (Moravian College), an M.S.E. in Chemical and Biochemical Engineering (University of Pennsylvania), and a J.D. (Catholic University, Columbus School of Law) . Company performance disclosures show cumulative TSR value of a $100 investment and net income for recent years, providing context during his tenure: TSR values of $25.20, $23.34, and $9.64 for 2022–2024, and net income of $(53)M, $(51)M, and $(41)M, respectively .

Company performance (context)

Past Roles

External Roles

• No external public company board roles disclosed in the 2025 proxy biography .

Fixed Compensation

• Sandercock is not listed as a named executive officer (NEO) in the 2025 proxy; the Summary Compensation Table covers CEO, CFO, CMO, and certain former executives only, so his base salary and bonus are not disclosed .
• The proxy describes general executive compensation practices for NEOs (mix of base salary, discretionary annual bonus, and long-term equity—primarily stock options), but does not provide individualized data for Sandercock .

Performance Compensation

• The 2025 Stock Incentive Plan authorizes options, SARs, restricted stock, RSUs, other stock-based awards, and cash awards; while this defines available vehicles, the proxy does not disclose Sandercock-specific grants, targets, or payouts .
• Company executive agreements include clawback provisions subject to applicable laws; this is disclosed in an executive employment agreement filed with the Q3 2025 10-Q (policy-level signal), but Sandercock-specific clawback terms are not detailed .

Equity Ownership & Alignment

• The Security Ownership table lists directors and NEOs; Sandercock (an executive officer but not a director or NEO) is not included, so his beneficial share ownership, options exercisable/unexercisable, and pledged shares are not disclosed in the 2025 proxy .
• Company equity plan scale (context): As of December 31, 2024, 10,271,724 securities to be issued upon exercise of outstanding awards under shareholder-approved plans, with 365,114 remaining available at year-end; the plan’s share reserve increased by 6,782,374 shares on January 1, 2025 per plan mechanics (company-level, not Sandercock-specific) .

Employment Terms

• The 2025 proxy provides an executive officer biography for Sandercock but does not include his employment agreement, severance or change-of-control provisions, or non-compete terms; such terms are not disclosed for him in the available filings reviewed .
• Company-level executive employment templates (e.g., Q3 2025 CEO agreement) show standard severance multiples (12 months base plus prorated target bonus), COBRA premium coverage, and clawback, but Sandercock’s personal terms are not specified in filings accessed .

Investment Implications

• Disclosure limits: As a non-NEO executive officer, Sandercock’s individual compensation, equity holdings, and severance/change-of-control economics are not itemized in the 2025 proxy, constraining pay-for-performance and alignment assessment .
• Governance/experience: Long-tenured corporate counsel with deep IP litigation and portfolio management background (Perkins Coie) supports execution on legal, IP, and transactional matters—key risk mitigation in biotech partnering and financing cycles .
• Incentive context: Cue’s compensation philosophy emphasizes long-term equity (options) to align with shareholders; the 2025 Stock Incentive Plan broadens equity award tools, but without Sandercock-specific grant data, insider trading forms would be necessary to assess selling pressure, vesting overhang, and alignment signals .
• Next steps for trading signals: To evaluate retention risk and selling pressure, retrieve Sandercock’s Form 4 filings for transactions, beneficial ownership, pledged/hedged positions, and option status; analyze any Item 5.02 8-Ks referencing compensatory arrangements if and when disclosed in future filings.